Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC42 and Atorvastatin DDI Study
NCT05464628Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asc42 in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), sponsored by Gannex Pharma Co., Ltd. Primary endpoints: Peak Plasma Concentration at 120 hours, Area Under the Curve (AUC0-inf) at 120 hours and 1 more. Started Aug 2022; status: completed.
02
Drugs
asc42
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05464628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464628.